Tuesday, May 19, 2020 @ 10:00 am
Mymetics (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that it has signed a Research Collaboration Agreement with Baylor College of Medicine for evaluating their rationally designed recombinant protein-based SARS-CoV and SARS-CoV-2 antigens and combining them with Mymetics’ virosomes for the development of a safe and effective Covid-19 vaccine.
Since the end of April, Mymetics has started a project for the rapid development of a Covid-19 virosome-based vaccine and is thereby partnering with leading academic institutions to explore and select the best SARS-CoV antigens, which could not only be efficacious in protecting against Covid-19 but also safe, affordable and accessible for use in the global population.
Baylor College of Medicine in Texas is a leading institution with a track record for developing low cost, safe and effective vaccines against emerging and neglected tropical diseases through collaboration with the Texas Children’s Center for Vaccine Development. The vaccine center already has been successful in developing potential vaccine against SARS-CoV and with this expertise has already initiated development of a SARS-CoV-2 recombinant protein-based vaccine.
“Our vaccine center has traditionally focused on advancing recombinant protein-based vaccines, but we recognize that for them to be effective, appropriate delivery platforms need to be considered, especially to ensure long-term immunity. Through the collaboration with Mymetics we will evaluate the coupling of our COVID-19 vaccine candidates to their flexible carrier to bring a new dimension towards accelerating vaccines for global access,” said Dr. Maria Elena Bottazzi, Professor, Pediatrics & Molecular Virology & Microbiology at Baylor College of Medicine and co-director of Texas Children’s Hospital Center for Vaccine Development.
“There is no question that if we want to get back to a life as before and a normal functioning economy, the world needs the rapid development of a safe and efficacious vaccine against Covid-19. The only serious way to get there fast is to have global collaborations to bring cross functional expertise together, establish result focused projects to explore and select the best vaccine candidates coupled with safe platform technologies and move them forward to clinical trials,” said Ronald Kempers, CEO of Mymetics Corporation. “Mymetics virosomes have proven to be a safe, efficacious and flexible vaccine carrier with other infectious diseases and we believe, with the right antigens and the right collaborations, we can have a serious attempt at developing a virosome-based Covid-19 vaccine. We are very much looking forward to this collaboration with the team at Baylor College of Medicine.”
This collaboration is supported through the combined resources of Mymetics, Baylor and Texas’s Children’s Center for Vaccine Development and covers the initial preclinical development. To speed-up the development of a potential Covid-19 vaccine, Mymetics and Baylor are seeking additional funding opportunities to start in parallel the GMP manufacturing and preparations for clinical trials. The aim is to have a virosome-based Covid-19 vaccine candidate evaluated in humans within 12 months.